Shares of the company are trading at $5.30 a bit higher than the 50 day moving average of $4.90 and which is just a bit higher than the 200 day moving average of $5.13. The 50 day moving average went up $0.40 or +8.22% whereas the 200 day average was up by +3.26%. Trading was light with 438K shares changing hands in the last trading session. Shares saw a steep decrease in trading volume of 31.23% under the normal average daily volume.
Short traders are more bearish on Endologix, Inc. of late if you watch the motion in short interest. The stock had a rise in short interest between September 29, 2017 and October 13, 2017 of 8.19%. Short shares grew from 13,525,718 to 14,633,812 over that period. With short interest at 14,633,812 and short average daily volume at 1,188,666, the short-interest ratio is 12.0 and the short interest percentage is 0.18% as of October 13.
These firms have modified their investment in ELGX. Rhenman & Partners Asset Management Ab divested its investment by selling 82,400 shares a decrease of 5.2%. Rhenman & Partners Asset Management Ab now controls 1,492,600 shares worth $6,657,000. The total value of its holdings decreased 13.0%. Bank Of Montreal /can/ grew its position by buying 600 shares an increase of 41.5% in the quarter. Bank Of Montreal /can/ owns 2,045 shares with a value of $9,000. The value of the position overall is up by 28.6%.
As of the end of the quarter Rathbone Brothers Plc had sold a total of 400 shares trimming its stake by 2.3%. The value of the investment in (ELGX) decreased from $85,000 to $76,000 a change of 10.6% quarter over quarter. As of quarter end Simplex Trading, LLC had disposed of 28,996 shares trimming its position 92.4%. The value in dollars went from $152,000 to $10,000 decreasing 93.4% since the last quarter.
In the latest earnings report the EPS was $-0.94 and is estimated to be $-0.62 for the current year with 83,434,000 shares now outstanding. Analysts expect next quarter’s EPS to be $-0.17 with next year’s EPS anticipated to be $-0.48.
Endologix, Inc., launched on June 2, 1993, is involved in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Business’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). Sales of the Business’s EVAR and EVAS platforms (including extensions and accessories) to hospitals in the United States and Europe, and to third-party international distributors provide the sole source of its revenue. It offers various accessories to facilitate the optimal delivery of its EVAR and EVAS products, including compatible guidewires, snares, and catheter introducer sheaths..